<?xml version="1.0" encoding="UTF-8"?>
<!--generator='jetpack-16.2'-->
<!--Jetpack_Sitemap_Buffer_News_XMLWriter-->
<?xml-stylesheet type="text/xsl" href="//www.biotechreality.com/news-sitemap.xsl"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd">
 <url>
  <loc>https://www.biotechreality.com/2026/10/sanofi-regeneron-alliance-expansion.html</loc>
  <lastmod>2026-10-02T06:24:24Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>BiotechReality - Information Intelligence System for Biopharma</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Sanofi Regeneron Alliance Expansion Adds Four Long-Acting Immunology Antibodies, Including REGN20423, in $1 Billion Upfront Deal</news:title>
   <news:publication_date>2026-10-02T06:24:20Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://www.biotechreality.com/2026/10/abbvie-abbv-295-phase-1-obesity-data.html</loc>
  <lastmod>2026-09-30T19:18:22Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>BiotechReality - Information Intelligence System for Biopharma</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>AbbVie ABBV-295 Phase 1 Data Show Long-Acting Potential for Obesity Treatment at EASD 2026</news:title>
   <news:publication_date>2026-09-30T19:18:18Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://www.biotechreality.com/2026/09/cagrisema-easd-2026-novo-nordisk-food-noise-organ-bone-data.html</loc>
  <lastmod>2026-09-30T18:26:19Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>BiotechReality - Information Intelligence System for Biopharma</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Novo Nordisk Reports CagriSema EASD 2026 Data Showing Reduced &amp;#039;Food Noise&amp;#039; and Organ and Bone Health Benefits</news:title>
   <news:publication_date>2026-09-30T18:26:15Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://www.biotechreality.com/2026/09/roche-fenebrutinib-fda-filing-multiple-sclerosis.html</loc>
  <lastmod>2026-09-30T15:24:48Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>BiotechReality - Information Intelligence System for Biopharma</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Roche Fenebrutinib FDA Filing Accepted Under Priority Review for Relapsing and Primary Progressive Multiple Sclerosis.</news:title>
   <news:publication_date>2026-09-30T15:24:43Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
</urlset>
